Intervention Review

DNA-repair pathway inhibitors for the treatment of ovarian cancer

  1. Igor Martinek2,
  2. Krishnayan Haldar2,
  3. Kezia Gaitskell3,
  4. Andrew Bryant4,
  5. Shibani Nicum5,
  6. Sean Kehoe2,
  7. Jo Morrison1,*

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 16 JUN 2010

Assessed as up-to-date: 10 MAY 2010

DOI: 10.1002/14651858.CD007929.pub2


How to Cite

Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J. DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD007929. DOI: 10.1002/14651858.CD007929.pub2.

Author Information

  1. 1

    University of Oxford, Nuffield Department of Obstetrics and Gynaecology, Oxford, UK

  2. 2

    Oxford Cancer and Haematology Centre, Oxford Gynaecological Oncology Centre, Level 0, Oxford, UK

  3. 3

    UCL Medical School, North Central Thames Foundation School, London, UK

  4. 4

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  5. 5

    Oxford Cancer and Haematology Centre, NHS Department of Oncology, Level 2, Oxford, UK

*Jo Morrison, Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe Hospital, Oxford, OX3 9DU, UK. jo.morrison@obs-gyn.ox.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 16 JUN 2010

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A Radziwon-Balicka, C Medina, L O'Driscoll, A Treumann, D Bazou, I Inkielewicz-Stepniak, A Radomski, H Jow, MW Radomski, Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance, British Journal of Pharmacology, 2012, 167, 4